Alembic Pharmaceuticals has informed that the Company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at its Injectable Facility (F-3) at Karkhadi from 18th August, 2022 to 30th August, 2022. This was a pre-approval inspection for ANDAs filed with the USFDA. The Company has already started receiving ANDA approvals manufactured at this facility.
The above information is a part of company’s filings submitted to BSE.